Eyenovia buys US commercialisation rights to Formosa’s APP13007
Under the agreement, US-based Eyenovia has obtained the exclusive US rights to distribute and sell APP13007 in a…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Aug 23
Under the agreement, US-based Eyenovia has obtained the exclusive US rights to distribute and sell APP13007 in a…
17 Aug 23
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult…
16 Aug 23
The partnership involves three separate multi-year collaborations, which allow Tentarix to receive a total of $66m in upfront…
16 Aug 23
The partnership enables CytoMed to leverage CNK's PiggyBac technology, leveraging a non-viral gene editing approach, to permanently integrate…
16 Aug 23
The agreement offers Gritstone bio unrestricted access to Genevant's LNP technology, which will be applied alongside Gritstone bio's…
16 Aug 23
Precision Eligible to Receive up to $227m in Upfront Economics and Milestone Payments for Azer-Cel in Addition to…
14 Aug 23
As part of the collaboration, Logomix will initially contribute genome editing capabilities to assist HebeCell in creating the…
11 Aug 23
Under the agreement, Antengene will retain its responsibilities for R&D, regulatory approvals and affairs, product supply, and distribution…
10 Aug 23
Under the agreement, T-MAXIMUM Biotech will get several CRISPR reagents from GenScript to aid in the development of…
10 Aug 23
The proposed acquisition will enhance the ongoing partnership between Decibel and Regeneron and the partnership aims to expedite…